Sansheng Guojian Announcement: The company’s humanized anti-IL-17A monoclonal antibody, Anmucita Injection (brand name: Yisaitu), has received approval from the National Medical Products Administration for new drug listing. It is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are suitable for systemic therapy or phototherapy.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Sansheng Guojian: Anmuchi Ta Monoclonal Antibody Injection New Drug Application Approved
Sansheng Guojian Announcement: The company’s humanized anti-IL-17A monoclonal antibody, Anmucita Injection (brand name: Yisaitu), has received approval from the National Medical Products Administration for new drug listing. It is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are suitable for systemic therapy or phototherapy.